Literature DB >> 9682701

Clinicopathologic features of retinoblastoma after primary chemoreduction.

N E Bechrakis1, N Bornfeld, A Schueler, S E Coupland, G Henze, M H Foerster.   

Abstract

BACKGROUND: Primary chemotherapy is a new treatment approach in retinoblastoma, aiming to avoid radiogenic adverse effects, such as second tumor-associated mortality, as observed following external beam irradiation.
OBJECTIVE: To describe the clinical and histopathologic regression pattern after primary chemotherapy in retinoblastoma.
METHODS: Five patients with sporadic bilateral retinoblastoma underwent planned enucleation of their functionally blind eye after 2, 3 (in 2 patients), 4, and 6 courses of primary chemotherapy with carboplatin, etoposide, cyclophosphamide, and vincristine. The eyes were examined histopathologically, using light microscopy and immunohistochemical analysis with proliferation markers.
RESULTS: One patient had a type 1 (cottage cheese) regression and 4 patients had either a type 2 (fish flesh) or a type 3 (combined) regression pattern. Histopathologic examination revealed a complete tumor necrosis in 1 patient with type 1 regression after 3 courses of chemotherapy and in 1 patient with type 3 regression after 4 courses of chemotherapy. The remaining 3 patients with type 2 or type 3 regression had histologically still active proliferative tumor cells after 2, 3, and 6 courses of chemotherapy.
CONCLUSION: This article correlates histopathologically the clinically described efficacy of primary chemotherapy in the treatment of retinoblastoma, underlining, however, the necessity of careful observation and the use of ancillary treatment whenever there is no complete tumor regression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9682701     DOI: 10.1001/archopht.116.7.887

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  13 in total

Review 1.  Chemotherapy for retinoblastoma: a current topic.

Authors:  P T Finger; G Czechonska; H Demirci; A Rausen
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Retinoblastoma and optic nerve enhancement on MRI: not always extraocular tumour extension.

Authors:  P de Graaf; A C Moll; S M Imhof; P van der Valk; J A Castelijns
Journal:  Br J Ophthalmol       Date:  2006-06       Impact factor: 4.638

3.  Pathological findings in enucleated eyes after intravitreal melphalan injection.

Authors:  Fariba Ghassemi; Fahimeh Asadi Amoli
Journal:  Int Ophthalmol       Date:  2013-09-17       Impact factor: 2.031

4.  Retinoblastoma. Fifty years of progress. The LXXI Edward Jackson Memorial Lecture.

Authors:  Hans E Grossniklaus
Journal:  Am J Ophthalmol       Date:  2014-07-24       Impact factor: 5.258

5.  Thermochemotherapy in hereditary retinoblastoma.

Authors:  A O Schueler; C Jurklies; H Heimann; R Wieland; W Havers; N Bornfeld
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

6.  The National Registry of Retinoblastoma in Japan (1983-2014).

Authors: 
Journal:  Jpn J Ophthalmol       Date:  2018-05-30       Impact factor: 2.447

7.  The value of "en toto" globe submission in the assessment of high-risk retinoblastoma cases and staging.

Authors:  Hind Manaa Alkatan; Hani ALBalawi; Azza M Y Maktabi
Journal:  Int Ophthalmol       Date:  2017-03-14       Impact factor: 2.031

Review 8.  [Retinoblastoma].

Authors:  N Bornfeld; A Schüler; R Bölöni; C Jurklies; R Wieland; W Sauerwein; D Lohmann
Journal:  Ophthalmologe       Date:  2006-01       Impact factor: 1.059

9.  Globe conserving treatment of the only eye in bilateral retinoblastoma.

Authors:  V Lee; J L Hungerford; C Bunce; F Ahmed; J E Kingston; P N Plowman
Journal:  Br J Ophthalmol       Date:  2003-11       Impact factor: 4.638

10.  [Retinoblastoma].

Authors:  N Bornfeld; D Lohmann; N E Bechrakis; E Biewald
Journal:  Ophthalmologe       Date:  2020-04       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.